| Broad-spectrum coronavirus antiviral drug discovery |
51 |
| Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery |
49 |
| Molecular dynamics simulations and novel drug discovery |
37 |
| Recent applications of click chemistry in drug discovery |
27 |
| An overview of late-stage functionalization in today's drug discovery |
20 |
| Future challenges with DNA-encoded chemical libraries in the drug discovery domain |
20 |
| The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy |
19 |
| Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer |
16 |
| Targeting adenosine A(2A) receptor antagonism for treatment of cancer |
15 |
| Hot-spot analysis for drug discovery targeting protein-protein interactions |
14 |
| Anticancer drug discovery using multicellular tumor spheroid models |
14 |
| PROTACs- a game-changing technology |
13 |
| Phenotypic screening approaches for Chagas disease drug discovery |
12 |
| Recent developments in biological aspects of chalcones: the odyssey continues |
12 |
| Current approaches for choosing feature selection and learning algorithms in quantitative structure-activity relationships (QSAR) |
12 |
| Non-alcoholic fatty liver disease (NAFLD) models in drug discovery |
11 |
| Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement? |
11 |
| Developments in lncRNA drug discovery: where are we heading? |
11 |
| Repositioning rifamycins for Mycobacterium abscessus lung disease |
11 |
| 4D-quantitative structure-activity relationship modeling: making a comeback |
10 |
| The discovery and development of topical medicines for wound healing |
10 |
| Novel approaches for designing drugs that interfere with pH regulation |
10 |
| Fluorescent probes for G-protein-coupled receptor drug discovery |
9 |
| Animal models for Niemann-Pick type C: implications for drug discovery & development |
9 |
| Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery |
9 |
| Have there been improvements in Alzheimer's disease drug discovery over the past 5 years? |
9 |
| Computational modeling of human oral bioavailability: what will be next? |
9 |
| Murine models of psoriasis and their usefulness for drug discovery |
9 |
| The compromise of virtual screening and its impact on drug discovery |
9 |
| Recent developments with tau-based drug discovery |
9 |
| New approaches for identifying and testing potential new anti-asthma agents |
8 |
| Organ-on-a-chip technologies that can transform ophthalmic drug discovery and disease modeling |
8 |
| Advances in preclinical approaches to Chagas disease drug discovery |
8 |
| Gaussian accelerated molecular dynamics for elucidation of drug pathways |
8 |
| Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery |
8 |
| Successes and failures of uterine leiomyoma drug discovery |
8 |
| Challenges with multi-objective QSAR in drug discovery |
8 |
| Halogen bonding in halocarbon-protein complexes and computational tools for rational drug design |
7 |
| Binding affinity in drug design: experimental and computational techniques |
7 |
| Vortioxetine: a novel antidepressant for the treatment of major depressive disorder |
7 |
| DataWarrior: an evaluation of the open-source drug discovery tool |
7 |
| Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis |
7 |
| Perspectives on the recent developments with green tea polyphenols in drug discovery |
7 |
| Discovery and development of varenicline for smoking cessation |
7 |
| Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches |
7 |
| Advances with support vector machines for novel drug discovery |
6 |
| Docking studies for melatonin receptors |
6 |
| Models of retinal diseases and their applicability in drug discovery |
6 |
| Designing safer analgesics: a focus on mu-opioid receptor pathways |
6 |
| Developments with 3D bioprinting for novel drug discovery |
6 |
